Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised

Key Takeaways Alkermes posted Q3 EPS of $0.49, beating estimates, with revenue up 4% year over year to $394.2 million.Sales of Vivitrol, Aristada, and Lybalvi rose 7%, 16%, and 32%, respectively, surpassing expectations.ALKS lifted the 2025 revenue forecast to $1.43 to $1.49B and raised sales outlooks for all three key drugs.Alkermes plc (ALKS) reported earnings from continuing operations of 49 cents per share for the third quarter of 2025, which beat the Zacks Consensus Estimate of 42 cents. The company re ...